Jonathan LoTempio
@realjlo.bsky.social
71 followers 130 following 6 posts
Fellow in the bioethics of human data at Penn. Bioinformatics, ethics, policy, and science. Interested in making pangenomes and how human data flows.
Posts Media Videos Starter Packs
realjlo.bsky.social
🧵2/4: But how to preserve data? #NIH flagship Database of #Genotypes and #Phenotypes #dbGaP allows for data to be restricted to nonprofit use only, preserving scientific benefit of #23andMe data as well as corp value.

But #doge #RIFs #today will make this even harder, hurting everyone everywhere.
realjlo.bsky.social
🧵1/4: 'Such a trove of data may be put to good use... The firm “did an incredible thing in that they got people to pay to participate in research”, says Jonathan LoTempio, of @upenn.bsky.social . 100s of studies have drawn on 23andMe.'

www.economist.com/business/202...
How safe is your DNA in a bankruptcy?
23andMe’s demise raises thorny legal questions
www.economist.com
Reposted by Jonathan LoTempio
altnps.bsky.social
OPM is planning to fire all employees on probation (less than one year of employment). Agencies have until noon on Wednesday to submit a list of probationary employees to the OPM and indicate whether they wish to retain them—though it has been stated that this will not make a difference.
realjlo.bsky.social
Thx for ur interest. I don't check r'gate, do please email me at lotempio @ upenn . edu for a copy. It's the email listed in the paper, too! 😉

The paper will be on US NIH PMC in a few months, as per the agreement with Nature and NIH requirements. Open science, whatever that is, is hard!
Reposted by Jonathan LoTempio
moezdawood.bsky.social
🚨 Excited to announce the Marker paper for the GREGoR Consortium! arxiv.org/abs/2412.14338

Accelerating #RareDisease diagnostics with cutting-edge #Genomics and global data sharing of omics and deep phenotyping from ~7500 individuals on NHGRI AnVIL and much more to come! 🧬
GREGoR: Accelerating Genomics for Rare Diseases
Rare diseases are collectively common, affecting approximately one in twenty individuals worldwide. In recent years, rapid progress has been made in rare disease diagnostics due to advances in DNA seq...
arxiv.org